These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1078 related articles for article (PubMed ID: 24578243)

  • 21. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.
    Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ
    J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.
    Lapa C; Linsenmann T; Monoranu CM; Samnick S; Buck AK; Bluemel C; Czernin J; Kessler AF; Homola GA; Ernestus RI; Löhr M; Herrmann K
    J Nucl Med; 2014 Oct; 55(10):1611-6. PubMed ID: 25125481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of [
    Shymanskaya A; Worthoff WA; Stoffels G; Lindemeyer J; Neumaier B; Lohmann P; Galldiks N; Langen KJ; Shah NJ
    Mol Imaging Biol; 2020 Feb; 22(1):198-207. PubMed ID: 30989437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy.
    Floeth FW; Pauleit D; Wittsack HJ; Langen KJ; Reifenberger G; Hamacher K; Messing-Jünger M; Zilles K; Weber F; Stummer W; Steiger HJ; Woebker G; Müller HW; Coenen H; Sabel M
    J Neurosurg; 2005 Feb; 102(2):318-27. PubMed ID: 15739561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience.
    Henriksen OM; Larsen VA; Muhic A; Hansen AE; Larsson HBW; Poulsen HS; Law I
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):103-112. PubMed ID: 26363903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
    Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
    Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
    Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
    Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential for differentiation of glioma recurrence from radionecrosis using integrated
    Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
    Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between 123I-CLINDE SPECT, 18F-FET PET, and Gadolinium-Enhanced MR Imaging.
    Jensen P; Feng L; Law I; Svarer C; Knudsen GM; Mikkelsen JD; de Nijs R; Larsen VA; Dyssegaard A; Thomsen G; Fischer W; Guilloteau D; Pinborg LH
    J Nucl Med; 2015 Sep; 56(9):1386-90. PubMed ID: 26182972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
    Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
    J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of
    Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas.
    Pyka T; Gempt J; Hiob D; Ringel F; Schlegel J; Bette S; Wester HJ; Meyer B; Förster S
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):133-141. PubMed ID: 26219871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
    Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
    Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
    Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH
    Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FET PET differentiation of ring-enhancing brain lesions.
    Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
    J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spatial distribution of malignant tissue in gliomas: correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging.
    Tietze A; Boldsen JK; Mouridsen K; Ribe L; Dyve S; Cortnum S; Østergaard L; Borghammer P
    Acta Radiol; 2015 Sep; 56(9):1135-44. PubMed ID: 25270372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-tumor histogram analysis of the cerebral blood volume map: tumor volume defined by 11C-methionine positron emission tomography image improves the diagnostic accuracy of cerebral glioma grading.
    Wu R; Watanabe Y; Arisawa A; Takahashi H; Tanaka H; Fujimoto Y; Watabe T; Isohashi K; Hatazawa J; Tomiyama N
    Jpn J Radiol; 2017 Oct; 35(10):613-621. PubMed ID: 28879406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.